Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
- Status
- COMPLETED
- Phase
- PHASE2
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
- Status
- COMPLETED
- Phase
- N/A
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE1
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
- Status
- COMPLETED
- Phase
- PHASE2
Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea
- Status
- COMPLETED
- Phase
- N/A
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE1
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
- Status
- COMPLETED
- Phase
- NA
SCT Plus Immune Therapy in Average Risk AML/MDS
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
- Status
- COMPLETED
- Phase
- N/A
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Three Dosing Schedules of Oral Rigosertib in MDS Patients
- Status
- WITHDRAWN
- Phase
- PHASE1
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
- Status
- COMPLETED
- Phase
- PHASE2
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- N/A